ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1318

Prediction of Large Joint Destruction in Patients with Rheumatoid Arthritis Using FDG-PET/CT: A Prospective Study

Takahito Suto, Koichi Okamura, Yukio Yonemoto, Chisa Okura and Kenji Takagishi, Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: 18FDG PET/CT scan, Disease Activity, joint destruction, rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The assessments of joint damage in patients with rheumatoid arthritis (RA) are mainly restricted to small joints in the hands and feet. However, the development of arthritis in RA patients often involves the large joints, such as the shoulder, elbow, hip, knee and ankle. Few studies have been reported regarding the degree of radiographic damage in large joints in patients with RA. 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) precisely visualizes the disease activity in large joints affected by RA. In this study, the associations between destruction of the large joints and the findings of FDG-PET/CT as well as laboratory parameters were investigated, and factors associated with large joint destruction after the administration of biological therapy were identified in patients with RA.

Methods: A total of 264 large joints in 23 RA patients (six males and 17 females; mean age of 66.9 ± 7.9 years) were assessed in this study. All patients were diagnosed according to the American College of Rheumatology criteria revised in 1987. FDG-PET/CT was performed at baseline and six months after the initiation of biological therapy. The extent of FDG uptake in large joints (shoulder, elbow, wrist, hip, knee and ankle) was analyzed using the maximum standardized uptake value (SUVmax). Radiographs of the 12 large joints per patient obtained at baseline and after two years were assessed according to Larsen’s method. A logistic regression analysis was performed to determine the factors most significantly contributing to the progression of joint destruction within two years.

Results: Among the 264 joints, radiographic progression of joint destruction was detected in 33 joints. The SUVmax at baseline and six months and the disease activity score (DAS) 28 – erythrocyte sedimentation rate (ESR) at six, 12 and 24 months were significantly higher in the group with progressive joint destruction. The SUVmax at baseline and DAS28-ESR at six months were found to be factors associated with joint destruction at two years (p < 0.05).

Conclusion: The FDG uptake in the joints with destruction was higher than that observed in the joints without destruction. The SUV max at baseline and the DAS28–ESR at six months after the biological treatment were identified to be significant factors predicting destruction of the large joints at two years.

References

Beckers C, Ribbens C, André B, et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med. 2004;45(6):956-64.

Matsui T, Nakata N, Nagai S, et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 2009;50(6):920-6.

Okamura K, Yonemoto Y, Arisaka Y, et al. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford). 2012;51(8):1484-91.


Disclosure: T. Suto, None; K. Okamura, None; Y. Yonemoto, None; C. Okura, None; K. Takagishi, None.

To cite this abstract in AMA style:

Suto T, Okamura K, Yonemoto Y, Okura C, Takagishi K. Prediction of Large Joint Destruction in Patients with Rheumatoid Arthritis Using FDG-PET/CT: A Prospective Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prediction-of-large-joint-destruction-in-patients-with-rheumatoid-arthritis-using-fdg-petct-a-prospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-large-joint-destruction-in-patients-with-rheumatoid-arthritis-using-fdg-petct-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology